enVVeno Medical Corporation (5HJ.F)
| Previous Close | 4.7200 |
| Open | 4.6800 |
| Bid | 4.6600 x N/A |
| Ask | 4.7800 x N/A |
| Day's Range | 4.6800 - 4.6800 |
| 52 Week Range | 2.4000 - 6.0500 |
| Volume | |
| Avg. Volume | 32 |
| Market Cap | 62.324M |
| Beta (5Y Monthly) | 1.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7800 |
| Earnings Date | May 06, 2024 - May 10, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIREPositive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
Overall 8.46 Average Revised Venous Clinical Severity Score (rVCSS) Improvement Per Patient for Patients Showing Clinical Meaningful Benefit (rVCSS Improvement ≥ 3 Points) including: 9.29 Points for Patients at the Two-Year Milestone 8.08 Points for ...
ACCESSWIRENew Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
IRVINE, CA / ACCESSWIRE / April 16, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that additional topline efficacy data from ...
ACCESSWIREenVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
Appointment bolsters Company's transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValve® PMA application seeking FDA approval for the VenoValve on track to be filed in Q4 of 2024 IRVINE, CA / ACCESSWIRE ...
